The industry should take a twin-track approach to the potential threat of the Trump administration's proposed move to reference pricing, writes Todd Edgar.
Todd Edgar
Advertisement
Todd Edgar is SVP at Precision for Value.
Articles by Todd Edgar
Advertisement
Latest Updated Articles
Reacting to Reference PricingPublished: December 5th 2018 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
2
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
3
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
4
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
5
